Compare Neurocrine Biosciences Inc (NBIX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Workiva Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Workiva Inc trades at $55.02 (market cap $3.21B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.4× Workiva Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | WK | |
|---|---|---|
Market Cap | $17.40B | $3.21B |
Sector | Health | Technology |
52-Week High | $180.55 | $93.31 |
52-Week Low | $123.10 | $44.31 |
Enterprise Value | $16.49B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Workiva (WK) trades at $57.19, up 0.02% on the day, with a bullish technical outlook from moving averages and strong analyst support. The company shows robust revenue growth, reaching $884.57M in 2025, and has consistently beaten earnings estimates in recent quarters. Recent news highlights its AI-powered platform growth and upcoming Q2 2026 results.
The stock presents a positive outlook with an 88.89% buy rating from analysts and a consensus price target of $71.00, suggesting 24% upside. Risks include high valuation multiples (P/E 238.29) and profitability challenges, with net income margin at 1.53% for 2026. Investors should weigh growth potential against execution risks in a competitive software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
